Evidence map›Paper›PMID 37367741›Full record

ReviewMedical sciences (Basel, Switzerland)2023

Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.

Adam Barsouk, John Sukumar Aluru, Prashanth Rawla, Kalyan Saginala, Alexander Barsouk

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medical sciences (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06332092 (A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma), which is not on this map. Cited by 558 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
558citing papers in PubMed, 7 pooled it
201.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06332092 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

TypeinterventionalSponsorFulgent Pharma LLC.Ran2024 to 2026Enrolled46ConditionsHead and Neck Squamous Cell CarcinomaArmsFID007
3 · Its place in the literature

Who cites it

558 citing papers in PubMed, 7 syntheses or guidelines pooled it, 596 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. [High expression of low-risk hpv in nasal inverted papilloma and its response to interferon therapy].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026
    Trial
  11. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

498 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Adam BarsoukInternal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
John Sukumar AluruElucid Bioimaging, Boston, MA 02216, USA.
Prashanth RawlaParrish Medical Center, Titusville, FL 32796, USA.ORCID 0000-0002-4361-8498
Kalyan SaginalaPlains Regional Medical Group Internal Medicine, Clovis, NM 88101, USA.
Alexander BarsoukHematologist-Oncologist, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Allegheny Health Network · USElucid Bioimaging · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies, involving the oral cavity, pharynx, hypopharynx, larynx, nasal cavity, and salivary glands, that together compose the seventh most common cancer diagnosis worldwide. With 890,000 new cases and 450,000 deaths annually per GLOBOCAN estimates, HNSCC accounts for roughly 4.5% of cancer diagnoses and deaths. In the developing world, the incidence of HNSCC is growing with increasing consumption of tobacco (smoked or chewed), alcohol, and areca nut (betel quid). Alcohol and tobacco have a synergistic effect, with the heavy consumption of both increasing HNSCC risk 40-fold. In developed nations, HPV-related HNSCC surpasses tobacco- and alcohol-related disease. HPV-related HNSCC more commonly affects the oropharynx, hypopharynx, and larynx than the oral cavity, and is associated with a significantly longer median survival (130 months vs. 20 months). Discrepancies in etiology as well as disparities in lifestyle choices and access to healthcare may account for the greater incidence and poorer survival of HNSCC among minority and lower-socioeconomic-status communities in developed nations. Pharmacotherapy and counseling together have been shown to be effective in promoting smoking and alcohol cessation. Education on cancer risk and community engagement have reduced areca nut consumption in Asia as well as in diaspora communities. HPV vaccination, starting at age 11-12 for both sexes, has been shown to reduce the prevalence of high-risk HPV serologies and prevent pre-cancerous lesions of the cervix, vagina, and vulva. As of 2020, 58.6% of eligible adolescents in the US have received the full two-vaccine series. Increased adoption of vaccination, education on safe sex practices, and routine visual oral screening for high-risk patients would curb growing HNSCC incidence in developed nations.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsPapillomavirus InfectionsAdolescentChildFemaleHumansMaleRisk FactorsSquamous Cell Carcinoma of Head and Neckepidemiologyhead and neck cancerincidencemortalitypreventionrisk factors

Identifiers

PMID37367741
PMCPMC10304137
OpenAlexW4380681798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.